Idiopathic intracranial hypertension (IIH) 1,2 has come under increased clinical scrutiny in the last 2 decades. This neurologic disorder is characterized by increased intracranial pressure of unknown ...

Reported accuracies were 86% (Random Forest) and 96% (convolutional neural networks), positioning retinal imaging as a candidate scalable tool for underserved populations. AI-powered polarized-light ...

NovaBridge Biosciences and Visara have announced topline results from their phase 2a study of VIS-101 for retinal vascular ...

Tattoo-associated uveitis was once considered rare; however, that appears to be no longer true, according to a new Australian ...

The 51 st annual American Association for Pediatric Ophthalmology and Strabismus (AAPOS) meeting will convene from March 18 ...

Following a second injection at eight weeks, the patient maintained stable vision and remained dry at 12 weeks, allowing for ...

MFDS IND approval enables a multicenter, randomized, double-blind, vehicle-controlled phase 2 study in ~150 DED patients, randomized 1:1:1 to two dosing arms versus control over 12 weeks. Prior phase ...

Desk workers reported 99.2 hours of weekly screen time, with weekday exposure comprising 93% of waking hours, underscoring ...

FDA approval supports US commercialization of TECNIS PureSee, an EDOF IOL for implantation during cataract surgery, with availability anticipated later in 2026. PureSee is positioned to preserve ...

Randomization (2:1:1) compared 78 mcg or 39 mcg BIM-IOL plus artificial tears versus standard monofocal IOL plus twice-daily timolol, with IOP change assessed at early visits. Mean IOP reduction at 12 ...

Severe, long-standing DME with cystoid changes, subretinal detachment, and high inflammatory cytokine burden tends to respond better to dual ANG2/VEGF-A inhibition than VEGF monotherapy. Faricimab ...

FDA authorization under an IND permits first-in-human phase I/II testing of SVT-001 in familial drusen, focusing on safety ...